Five things for pharma marketers to know: Wednesday, January 17, 2018
Celgene reportedly in talks to buy Juno; Novartis’ Kymriah receives fast-track reviews in U.S. and Europe; BI’s Gilotrif gets expanded approval in lung cancer
Vaccines
No Google, no problem: Pharma partners with China’s tech giants
In the absence of behemoths such as Facebook and Twitter, pharma is partnering with China’s tech giants to snare a slice of a more than $100 billion market
Five things for pharma marketers to know: Thursday, January 4, 2018
Allergan to cut 1,000 jobs; McKesson acquires RxCrossroads from CVS Health; Pfizer and Sangamo enter collaboration to develop ALS gene therapy
Five things for pharma marketers to know: Wednesday, December 13, 2017
Teva diminishes debt with job cuts and sale; FDA to study whether consumers can detect misleading ads; AbbVie, Roche present positive Phase-III data at ASH
Five things for pharma marketers to know: Monday, December 4, 2017
CVS to buy Aetna for $69 billion; J&J buys commercial rights for biotech’s experimental hypertension drug; Republicans repeal Obamacare’s individual mandate
Pfizer campaign aims to keep boomers healthy
Company enlists Patti LaBelle to increase awareness for the pneumococcal pneumonia vaccine
Five things for pharma marketers to know: Monday, November 13, 2017
Dynavax receives FDA approval for hepatitis-B vaccine; Novartis strikes R&D deal with gene-editing startup; White House nominates new HHS head
Five things for pharma marketers to know: Tuesday, November 7, 2017
Senator investigates Alkermes’ opioid-marketing tactics; FDA approves Roche cancer drugs; CVS to launch next-day delivery nationwide
Five things for pharma marketers to know: Tuesday, October 31, 2017
Pfizer Q3 revenue driven by Prevnar sales; President Trump’s opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah
Five things for pharma marketers to know: Monday, October 23, 2017
Biosimilars could save $54 billion in next decade; White House requests drug-pricing task force; FDA approves GSK shingle vaccine
